Loading...

ESSA Pharma

DB:E031
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
E031
DB
CA$20M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • ESSA Pharma has significant price volatility in the past 3 months.
E031 Share Price and Events
7 Day Returns
0.9%
DB:E031
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-12.3%
DB:E031
-10.2%
DE Biotechs
-6%
DE Market
E031 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ESSA Pharma (E031) 0.9% -19.7% -31.4% -12.3% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • E031 underperformed the Biotechs industry which returned -10.2% over the past year.
  • E031 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
E031
Industry
5yr Volatility vs Market

E031 Value

 Is ESSA Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ESSA Pharma. This is due to cash flow or dividend data being unavailable. The share price is €2.2965.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ESSA Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ESSA Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:E031 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.12
TSXV:EPI Share Price ** TSXV (2019-04-18) in CAD CA$3.2
TSXV:EPI Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.747 $2.39
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ESSA Pharma.

DB:E031 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:EPI Share Price ÷ EPS (both in USD)

= 2.39 ÷ -2.12

-1.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ESSA Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ESSA Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ESSA Pharma's expected growth come at a high price?
Raw Data
DB:E031 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ESSA Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ESSA Pharma's assets?
Raw Data
DB:E031 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.07
TSXV:EPI Share Price * TSXV (2019-04-18) in CAD CA$3.2
TSXV:EPI Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.747 $2.39
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:E031 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:EPI Share Price ÷ Book Value per Share (both in USD)

= 2.39 ÷ 1.07

2.23x

* Primary Listing of ESSA Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ESSA Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ESSA Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ESSA Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

E031 Future Performance

 How is ESSA Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ESSA Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ESSA Pharma expected to grow at an attractive rate?
  • Unable to compare ESSA Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ESSA Pharma's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare ESSA Pharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:E031 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:E031 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:E031 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-09-30 0 1
2019-09-30 0 1
DB:E031 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -10 -12
2018-09-30 -10 -12
2018-06-30 -11 -11
2018-03-31 -13 -5
2017-12-31 -13 -8
2017-09-30 -17 -4
2017-06-30 -18 -7
2017-03-31 -16 -14
2016-12-31 -19 -8
2016-09-30 -15 -13
2016-06-30 -17 -8
2016-03-31 -18 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ESSA Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if ESSA Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:E031 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from ESSA Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:E031 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-09-30
2019-09-30
DB:E031 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.12
2018-09-30 -2.55
2018-06-30 -3.23
2018-03-31 -2.00
2017-12-31 -5.53
2017-09-30 -3.09
2017-06-30 -4.67
2017-03-31 -9.80
2016-12-31 -5.39
2016-09-30 -9.77
2016-06-30 -6.69
2016-03-31 -8.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ESSA Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine ESSA Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. ESSA Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. ESSA Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ESSA Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ESSA Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

E031 Past Performance

  How has ESSA Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ESSA Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ESSA Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ESSA Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ESSA Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ESSA Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ESSA Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:E031 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -12.25 6.22 5.19
2018-09-30 -11.63 5.93 4.87
2018-06-30 -11.30 5.82 5.11
2018-03-31 -4.83 5.55 7.04
2017-12-31 -8.05 4.73 7.60
2017-09-30 -4.50 5.14 5.73
2017-06-30 -6.79 5.27 8.51
2017-03-31 -14.25 5.28 8.96
2016-12-31 -7.69 5.79 8.95
2016-09-30 -13.14 5.67 13.06
2016-06-30 -8.42 6.64 8.32
2016-03-31 -9.84 6.42 7.54
2015-12-31 -12.34 5.89 7.53
2015-09-30 -9.68 5.35 4.98
2015-06-30 -10.58 3.66 5.67
2015-03-31 -6.11 2.85 3.59
2014-12-31 -2.81 1.65 1.16
2014-09-30 -1.82 1.12 0.67
2014-06-30 -1.49 0.76 0.70
2013-09-30 -1.37 0.37 0.99
2012-12-31 -1.94 0.39 1.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ESSA Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ESSA Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ESSA Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ESSA Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ESSA Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

E031 Health

 How is ESSA Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ESSA Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ESSA Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ESSA Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ESSA Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ESSA Pharma Company Filings, last reported 3 months ago.

DB:E031 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.78 5.69 12.17
2018-09-30 9.15 6.32 14.83
2018-06-30 10.94 6.91 18.06
2018-03-31 13.37 7.49 21.69
2017-12-31 -6.32 8.06 1.87
2017-09-30 -4.27 7.96 3.96
2017-06-30 -2.18 7.84 7.33
2017-03-31 -5.90 7.80 12.62
2016-12-31 1.47 7.71 10.86
2016-09-30 -0.54 0.00 8.99
2016-06-30 3.26 0.00 12.38
2016-03-31 6.88 0.00 15.93
2015-12-31 0.67 0.00 2.61
2015-09-30 4.46 0.00 1.58
2015-06-30 4.36 0.00 6.20
2015-03-31 8.93 0.00 10.46
2014-12-31 3.02 0.00 3.45
2014-09-30 1.97 0.00 3.70
2014-06-30 0.20 0.00 0.30
2013-09-30 0.48 0.00 0.23
2012-12-31 1.31 0.00 0.82
  • ESSA Pharma's level of debt (84%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 84% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ESSA Pharma has sufficient cash runway for 1.2 years based on current free cash flow.
  • ESSA Pharma has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -15.6% each year.
X
Financial health checks
We assess ESSA Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ESSA Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

E031 Dividends

 What is ESSA Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ESSA Pharma dividends.
If you bought €2,000 of ESSA Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ESSA Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ESSA Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:E031 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:E031 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ESSA Pharma has not reported any payouts.
  • Unable to verify if ESSA Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ESSA Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ESSA Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ESSA Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ESSA Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ESSA Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

E031 Management

 What is the CEO of ESSA Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Parkinson
COMPENSATION $963,976
AGE 68
TENURE AS CEO 3.3 years
CEO Bio

Dr. David Ross Parkinson, M.D., has been an Independent Director of Tocagen Inc. since April 2015. He has been the Chief Executive Officer and President of ESSA Pharma Inc. since January 7, 2016. He serves as the Chairman of the Clinical Advisory Board and Director of Zyngenia, Inc. He has been an Independent Non-Executive Director at 3SBio Inc. since June 1, 2015. Dr. Parkinson has been a Director of Cerulean Pharma Inc. since October 29, 2014. He has been a Member of Scientific Advisory Board at Critical Outcome Technologies Inc. since March 23, 2015. He has been a Director of Threshold Pharmaceuticals Inc. since May 12, 2010. He has been a Director of CTI BioPharma Corp. since June 05, 2017. He has been a Director of ESSA Pharma Inc. since June 24, 2015 and DeNovo Biosciences, Inc. Dr. Parkinson serves as a Director of Myeloma Research Foundation. He serves as a Member of Scientific Advisory Board at Onconova Therapeutics, Inc. and served as its Member of Clinical Advisory Board until December 6, 2016. He is a member of the FDA's Science Board. Dr. Parkinson served as an Acting Chief Executive Officer at Zyngenia, Inc. Dr. Parkinson served Venture Advisor at New Enterprise Associates since 2016 and served as its Venture Partner since 2012 until 2016. He specialized on healthcare and biopharma. He served as an Interim Chief Medical Officer of Zyngenia, Inc. He served as the President and Chief Executive Officer of Nodality, Inc. from September 24, 2007 to 2012. Prior to October 2007, he served as Senior Vice President of Oncology Research & Development at Biogen Inc. since March 29, 2006. He served as a Vice President of Oncology Development & Commercialization of Amgen Inc. since August 4, 2005. He served as Vice President and Head of the Clinical Oncology Therapeutic Area of Amgen Inc. since May 21, 2003. He has previously led oncology clinical development activities at Novartis from 1997 to 2003, Amgen from 2003 to 2006 and Biogen Idec from 2006 to 2007. He directed global development efforts in oncology for all of Amgen's new product candidates and new indications for marketed products. Dr. Parkinson has a wealth of experience in drug development and an international reputation in clinical oncology, including a track record in developing new therapies in oncology. He joined Amgen from Novartis Pharmaceutical Corporation where he was Global Head, Translational Development and a member of their Oncology Business Unit Executive Committee. He served as Vice President of global clinical oncology development at Novartis Corporation. As head of oncology clinical research and development at Novartis, he led teams that successfully registered numerous important new therapies, including Gleevec(TM), the first successful protein kinase inhibitor and Zometa(R), a bisphosphonate indicated for the treatment of bone metastases. He served as a Member of Scientific Advisory Board at Mersana Therapeutics, Inc., since October 21, 2013. He served as a Director of Nodality, Inc. He served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011, as a Board Director of the Ontario Institute for Cancer Research. Dr. Parkinson served as a Director of Ambit Biosciences Corporation from March 2013 to November 10, 2014. He served as a Director of the American Association of Cancer Research (AACR) from 2006 to 2009. He served as a Member of Clinical Advisory Board at CytRx Corporation since February 2008. He served as a Director of AbbVie Biotherapeutics Inc. (alternate name, Abbott Biotherapeutics Corp.) since December 2008. He served as the President of the International Society of Biological Therapy and past Editor of the Journal of Immunotherapy. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as the Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. Dr. Parkinson joined the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute, where he also served as a member of the Biologics Evaluation Committee at the U.S. Food and Drug Administration. His skills in drug evaluation brought him to the attention of Novartis, where he occupied positions of increasing responsibility since 1997. He is the recipient of numerous honors and awards, including the Wiley Medal (Commissioner''s Citation of Merit) from the U.S. Food and Drug Administration in 1997 and teaching awards at both Tufts University and the University of Texas. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center and has authored over 100 peer-reviewed publications. He is a recipient of the FDA's Cody Medal. Dr. Parkinson pursued clinical training at the Royal Victoria Hospital, McGill University and at the New England Medical Center, where he was also an Assistant Professor at Tufts University School of Medicine and an attending physician in hematology/oncology. He completed a Hematology Fellowship at Royal Victoria Hospital at McGill University in Montreal and was a Research Fellow at the New England Medical Center at Tufts University in Boston. He delivered the 12th Andrew H. Weinberg Memorial Lecture at the Harvard University School of Medicine in 2008. Dr. Parkinson received his M.D from the University of Toronto, Faculty of Medicine in 1977, with Internal Medicine.

CEO Compensation
  • David's compensation has been consistent with company performance over the past year.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ESSA Pharma management team in years:

5.8
Average Tenure
61
Average Age
  • The average tenure for the ESSA Pharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

David Parkinson

TITLE
President
COMPENSATION
$964K
AGE
68
TENURE
3.3 yrs

David Wood

TITLE
Chief Financial Officer
COMPENSATION
$238K
AGE
61
TENURE
5.8 yrs

Peter Virsik

TITLE
Executive VP & COO
COMPENSATION
$576K
AGE
47
TENURE
2.7 yrs

Raymond Andersen

TITLE
CTO, Secretary & Director
COMPENSATION
$97K
AGE
71
TENURE
8.5 yrs

Marianne Sadar

TITLE
Chief Scientific Officer & Director
COMPENSATION
$187K
AGE
57
TENURE
8.5 yrs

Chandtip Chandhasin

TITLE
Executive

Erica Osbourne

TITLE
Executive

Erin Rudsinski

TITLE
Executive

Leah Dimascio

TITLE
Executive

Loleta Harris

TITLE
Executive
Board of Directors Tenure

Average tenure and age of the ESSA Pharma board of directors in years:

5.5
Average Tenure
62.5
Average Age
  • The tenure for the ESSA Pharma board of directors is about average.
Board of Directors

Richard Glickman

TITLE
Chairman
COMPENSATION
$60K
AGE
60
TENURE
8.5 yrs

David Parkinson

TITLE
President
COMPENSATION
$964K
AGE
68
TENURE
3.8 yrs

Raymond Andersen

TITLE
CTO, Secretary & Director
COMPENSATION
$97K
AGE
71
TENURE
8.5 yrs

Marianne Sadar

TITLE
Chief Scientific Officer & Director
COMPENSATION
$187K
AGE
57
TENURE
10.3 yrs

Gary Sollis

TITLE
Director
COMPENSATION
$49K
AGE
65
TENURE
7 yrs

Franklin Berger

TITLE
Independent Director
COMPENSATION
$55K
AGE
69
TENURE
4.1 yrs

Scott Requadt

TITLE
Director
COMPENSATION
$43K
AGE
50
TENURE
3.3 yrs

Otello Stampacchia

TITLE
Director
AGE
44
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ESSA Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ESSA Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

E031 News

Simply Wall St News

E031 Company Info

Description

ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Details
Name: ESSA Pharma Inc.
E031
Exchange: DB
Founded: 2009
CA$13,410,989
6,311,098
Website: http://www.essapharma.com
Address: ESSA Pharma Inc.
999 West Broadway,
Suite 720,
Vancouver,
British Columbia, V5Z 1K5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV EPI Common Shares TSX Venture Exchange CA CAD 28. Jan 2015
NasdaqCM EPIX Common Shares Nasdaq Capital Market US USD 28. Jan 2015
DB E031 Common Shares Deutsche Boerse AG DE EUR 28. Jan 2015
Number of employees
Current staff
Staff numbers
15
ESSA Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:04
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/15
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.